Φορτώνει......
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma
AIMS: To examine the effect of a strong cytochrome P450 (CYP) 3A inhibitor, ketoconazole, on the pharmacokinetics, safety and tolerability of venetoclax. METHODS: Twelve patients with non‐Hodgkin lymphoma (NHL) were enrolled in this Phase 1, open‐label, fixed‐sequence study. Patients received a sing...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Br J Clin Pharmacol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2017
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5346863/ https://ncbi.nlm.nih.gov/pubmed/27859472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13175 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|